[go: up one dir, main page]

WO2025093848A1 - Ensifentrine pour le traitement de la bronchectasie - Google Patents

Ensifentrine pour le traitement de la bronchectasie Download PDF

Info

Publication number
WO2025093848A1
WO2025093848A1 PCT/GB2024/051144 GB2024051144W WO2025093848A1 WO 2025093848 A1 WO2025093848 A1 WO 2025093848A1 GB 2024051144 W GB2024051144 W GB 2024051144W WO 2025093848 A1 WO2025093848 A1 WO 2025093848A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
patient
bronchiectasis
use according
method comprises
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/GB2024/051144
Other languages
English (en)
Inventor
Kathleen RICKARD
Tara Renae Rheault
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Verona Pharma Ltd
Original Assignee
Verona Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Verona Pharma Ltd filed Critical Verona Pharma Ltd
Publication of WO2025093848A1 publication Critical patent/WO2025093848A1/fr
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents

Definitions

  • the present invention relates to the treatment of bronchiectasis.
  • Ensifentrine (A/-(2- ⁇ (2E)-9,10-dimethoxy-4-oxo-2-[(2,4,6-trimethylphenyl)imino]-6,7- dihydro-2/7-pyrimido[6,1 -a]isoquinolin-3(4/7)-yl ⁇ ethyl)urea; also known as RPL554) is a dual PDE3/PDE4 inhibitor and is described in WO 00/58308 A1 .
  • ensifentrine As a combined PDE3/PDE4 inhibitor, ensifentrine has both bronchodilatory and antiinflammatory activity and is useful in the treatment of respiratory disorders including chronic obstructive pulmonary disease (COPD).
  • COPD chronic obstructive pulmonary disease
  • Ensifentrine has also been found to modulate cystic fibrosis transmembrane conductance regulator (CFTR, WO 2015/173551 A1 ).
  • Bronchiectasis is a chronic respiratory disorder characterised by permanent abnormal dilation of the bronchi (i.e. enlargement of the airways in the lung).
  • the prevalence of bronchiectasis has been estimated at over 100 cases per 100,000 population and the disease has a significant clinical and economic burden.
  • the main symptoms of bronchiectasis are chronic cough, sputum production, impaired mucociliary clearance, and bronchial infection. Patients may also suffer breathlessness (dyspnoea), fatigue, coughing up blood (haemoptysis) and chest pain. Bronchiectasis may arise from a large number of different etiologies.
  • Cystic fibrosis is a common cause, with most cystic fibrosis patients ultimately developing severe bronchiectasis. However, a significant proportion of bronchiectasis cases are in patients who do not have cystic fibrosis (referred to as non-CF bronchiectasis).
  • Non- CF causes of bronchiectasis can include infectious diseases such as pneumonia, measles and tuberculosis, although in some patients the cause of non-CF bronchiectasis is unknown.
  • non-CF bronchiectasis the primary cause of the enlargement of the airways is damage caused by persistent inflammation, and in particular persistent neutrophilic inflammation.
  • Bronchiectasis has limited treatment options. There are no drugs yet approved in the USA or Europe specifically for the treatment of this disease, and particularly for the treatment of non-CF bronchiectasis.
  • Ensifentrine has also been found to reduce cytokines associated with neutrophilic inflammation such as IL-8 and to reduce airway macrophage infiltration. These activities allow ensifentrine to target the neutrophilic inflammation underlying non-CF bronchiectasis while alleviating the key symptoms of chronic cough and increased sputum production.
  • the invention accordingly provides a compound for use in a method of preventing or treating bronchiectasis in a patient, which compound is ensifentrine or a pharmaceutically acceptable salt thereof, wherein the bronchiectasis is non-cystic fibrosis (non-CF) bronchiectasis.
  • Also provided by the invention is a compound for use in a method of treating bronchiectasis in a patient, which compound is ensifentrine or a pharmaceutically acceptable salt thereof, wherein the method comprises treating the bronchiectasis by (a) reducing the frequency of cough in the patient and/or (b) reducing sputum production and/or facilitating clearance of mucus from the lungs in the patient.
  • the compound is for use in the treatment of bronchiectasis, and in particular non- cystic fibrosis (non-CF) bronchiectasis.
  • Non-CF bronchiectasis is bronchiectasis in a patient who does not have cystic fibrosis.
  • a patient who does not have cystic fibrosis is a patient who does not have mutations in both alleles of the gene encoding cystic fibrosis transmembrane conductance regulator (CFTR).
  • CFTR cystic fibrosis transmembrane conductance regulator
  • the patient has typically been diagnosed as having the bronchiectasis.
  • the patient may for instance have been diagnosed with bronchiectasis based on observation of bronchial dilation using computed tomography.
  • the compound is for use in a method of preventing or treating non-CF bronchiectasis.
  • the compound may be for use in treating non-CF bronchiectasis.
  • the method may comprise treating the bronchiectasis by (a) reducing the frequency of cough in the patient and/or (b) reducing sputum production and/or facilitating clearance of mucus from the lungs in the patient.
  • the method may comprise treating the bronchiectasis by reducing the frequency of cough in the patient.
  • the method may comprise reducing sputum production in the patient.
  • the method may comprise treating the bronchiectasis by reducing the frequency of cough in the patient and reducing sputum production in the patient.
  • the severity of cough and sputum production in a patient may be assessed using the cough and sputum domain of the EXACT -Respiratory Symptoms (E-RS) scale as described in “E-RS (EXACT-Respiratory Symptoms), User Manual (Version 3.0), October 2014’’.
  • the cough and sputum domain of E-RS includes the questions 2, 3 and 4 of the E-RS and the total score may range from 0 to 11 .
  • the patient typically has a reduced score in the cough and sputum domain of E-RS, for instance a score reduced by at least 1 or at least 2 relative to the score in the cough and sputum domain of E-RS the day before the day on which the compound is first administered.
  • the reduced score is typically achieved following daily administration of the compound for at least 14 days, for instance for at least 8 weeks.
  • the patient may have a cough and sputum domain score of at least 3, at least 4, at least 5 or at least 6 on the day before the day on which the compound is first administered.
  • the patient may have a cough and sputum domain score of at least 8 or at least 9 on the day before the day on which the compound is first administered.
  • the patient typically has a score of at least 5 or at least 6 on the day before the day on which the compound is first administered.
  • the compound may reduce the score of the patient in the cough and sputum domain of the EXACT -Respiratory Symptoms (E-RS) scale, preferably wherein the score is reduced by at least 1 following administration of the compound.
  • the patient has a score of at least 5 in the cough and sputum domain of the EXACT -Respiratory Symptoms (E-RS) scale the day before the day on which the compound is first administered to the patient.
  • the patient may have a score of at least 5 in the cough and sputum domain of the EXACT-Respiratory Symptoms (E-RS) scale the day before the day on which the compound is first administered to the patient and the patient may have a score of no greater than 4 after daily administration of the compound for at least 12 weeks.
  • E-RS EXACT-Respiratory Symptoms
  • bronchiectasis exacerbations Some bronchiectasis patients suffer from bronchiectasis exacerbations.
  • a bronchiectasis exacerbation is an acute worsening of bronchiectasis symptoms which persists for at least two days.
  • a bronchiectasis exacerbation in a patient comprises worsening of two or more of cough, sputum volume (i.e. increased sputum volume) and sputum purulence (i.e. increased sputum purulence) for at least two days.
  • the compound may decrease the frequency and/or severity of bronchiectasis exacerbations in the patient.
  • the compound may decrease the frequency of bronchiectasis exacerbations in the patient.
  • the invention may provide a compound for use in a method of decreasing the frequency and/or severity of bronchiectasis exacerbations in a patient, which compound is ensifentrine or a pharmaceutically acceptable salt thereof.
  • Ensifentrine has been found to have an anti-inflammatory effect which is well suited to the treatment of bronchiectasis, and in particular non-CF bronchiectasis.
  • the compound may treat the bronchiectasis by reducing proinflammatory cytokines and chemokines such as IL-8, IL-6 and TNF-a in the lungs and/or reducing macrophage infiltration into the lungs.
  • the compound reduces neutrophilic inflammation in the patient.
  • the compound reduces neutrophilic inflammation in the lungs of the patient.
  • the bronchiectasis may be non-CF bronchiectasis and administration of the compound by inhalation may reduce neutrophilic inflammation in the lungs of the patient.
  • the compound may reduce the concentration of one or more of IL-6, IL-8 and TNF-a in the blood and/or lungs of the patient.
  • concentration of one or more of IL-6, IL-8 and TNF-a is reduced in the blood of the patient.
  • the compound may reduce the concentration of both IL-6 and IL-8 in the blood of the patient.
  • the compound may reduce the concentration of both IL-6 and IL-8 in the lungs of the patient.
  • the compound may reduce the concentration of TNF-a in the blood and/or lungs of the patient.
  • the compound may treat non-CF bronchiectasis by reducing neutrophilic inflammation in the patient and by reducing the frequency of cough in the patient.
  • the bronchiectasis may be idiopathic bronchiectasis.
  • the bronchiectasis is preferably non-CF bronchiectasis.
  • the bronchiectasis is typically non-CF bronchiectasis caused by one or more of: a lung infection; a lung disease; smoking; an inflammatory disease; and an obstruction in the lung.
  • the lung infection may be selected from a bacterial infection and a viral infection.
  • the bronchiectasis may be caused by an infection with a bacterium selected from Pseudomonas aeruginosa, Haemophilus influenzae, Mycobacterium tuberculosis and Streptococcus pneumoniae.
  • the lung infection may be pneumonia.
  • the inflammatory disease may be selected from ulcerative colitis, Crohn’s disease and rheumatoid arthritis.
  • the obstruction of the lung may be caused by a tumour or aspiration of a foreign body.
  • the non-CF bronchiectasis is caused by a lung disease selected from chronic obstructive pulmonary disease (COPD), asthma and interstitial lung disease.
  • COPD chronic obstructive pulmonary disease
  • the patient may be suffering from COPD.
  • the patient may be suffering from both COPD and bronchiectasis (for instance COPD and non-CF bronchiectasis).
  • the bronchiectasis is typically not caused by a congenital disorder.
  • the patient is not therefore suffering from any of cystic fibrosis, primary ciliary dyskinesia, Williams-Campbell syndrome, Marfan’s syndrome, Mounier-Kuhn syndrome, Alpha-1 antitrypsin deficiency, yellow nail syndrome and Young’s syndrome.
  • the patient may be male.
  • the patient may be female.
  • the patient may have an age of greater than or equal to 65 years.
  • the patient may have an age of less than 65 years.
  • the patient may be taking a background medication selected from one or more of a long-acting muscarinic antagonist (LAMA), a long-acting beta-agonist (LABA) and an inhaled corticosteroid (ICS).
  • LAMA long-acting muscarinic antagonist
  • LABA long-acting beta-agonist
  • ICS inhaled corticosteroid
  • the compound is ensifentrine or a pharmaceutically acceptable salt thereof.
  • Pharmaceutically acceptable salts are well known to the skilled person.
  • the compound is ensifentrine (i.e. ensifentrine free base).
  • the method typically comprises administering the compound to the patient by inhalation.
  • a pharmaceutical composition comprising the compound and one or more pharmaceutically acceptable excipients or diluents is typically administered to the patient by inhalation, for instance by nebuliser, pressurised metered dose inhaler (pMDI) or dry powder inhaler (DPI).
  • pMDI pressurised metered dose inhaler
  • DPI dry powder inhaler
  • the method comprises administering the compound to the patient by inhalation from a nebuliser.
  • Nebulisers aerosolise a liquid pharmaceutical composition into an aerosol that is inhaled into a patient's respiratory tract.
  • nebulisers include a soft mist nebuliser, a vibrating mesh nebuliser, a jet nebuliser and an ultrasonic wave nebuliser.
  • Suitable nebuliser devices include the Philips l-nebTM (Philips), the Philips SideStream (Philips), the AeroNeb® (Philips), the Philips InnoSpire Go (Philips), the Pari LC Sprint (Pari GmbH), the AERxRTM Pulmonary Delivery System (Aradigm Corp) and the Pari LC Plus Reusable Nebuliser (Pari GmbH).
  • the nebulizer may for instance be a PARI LC Sprint jet nebulizer with a PARI Vios® PRO Aerosol Delivery System PARI BOY® compressor.
  • the compound may be inhaled via the nebuliser for from 1 to 15 minutes.
  • the method comprises administering the compound to the patient once, twice or three times per day, for instance twice or three times per day.
  • the compound may be administered to the patient by inhalation once, twice or three times a day.
  • the method comprises administering the compound to the patient by inhalation twice a day.
  • the method may comprise administering a first dose of the compound in the morning (for instance within 3 hours following waking) and a second dose of the compound in the evening (for instance within 3 hours before bed).
  • the morning and evening doses are administered from 10 to 14 hours apart, for instance about 12 hours apart.
  • the compound may be used in any suitable therapeutically effective amount.
  • the daily dose of the compound is from 0.1 to 20 mg.
  • the method comprises administering a total daily dose of the compound of from 0.5 to 10 mg.
  • the total daily dose of the compound e.g. ensifentrine free base
  • the total daily dose of the compound is from 5 to 7 mg, for instance about 6 mg per day.
  • the term “about” may represent a variation of ⁇ 10% of the stated value.
  • the total daily dose of the compound may be 6.0 mg.
  • the compound is administered twice a day in two separate doses which are the same or similar.
  • the method may comprise administering the compound to the patient twice a day in a first dose of from 1 to 5 mg and a second dose of from 1 to 5 mg.
  • the method may comprise administering the compound to the patient twice a day with a first dose of from 2 to 4 mg and a second dose of from 2 to 4 mg.
  • the method comprises administering two doses of about 3 mg ensifentrine free base to the patient per day by inhalation.
  • the method preferably comprises administering a dose of about 3 mg of the compound to the patient twice a day (3 mg BID) by inhalation.
  • the method comprises administering by nebuliser a dose of about 3 mg the compound to the patient twice a day.
  • Each dose may be 3.0 mg free base ensifentrine administered by nebulizer.
  • the compound is typically used as a maintenance therapy.
  • the method comprises administering the compound to the patient at least once per day for at least 8 weeks.
  • the compound may be administered to the patient at least once per day for at least 16 weeks, preferably for at least 24 weeks.
  • the compound may be administered daily to the patient for at least 1 year.
  • the method may comprise administering the compound to the patient at least once every 24 hours, preferably at least twice every 24 hours, for at least 8 weeks, preferably for at least 16 weeks, more preferably for at least 24 weeks.
  • the compound is preferably administered as a suspension formulation, i.e. a suspension of particles comprising the compound in a diluent.
  • the compound may alternatively be delivered as a dry powder, for instance a dry powder comprising particles comprising the compound and particles of a carrier such as lactose.
  • the method typically comprises administering an inhalable pharmaceutical composition comprising a suspension of particles of the compound in a diluent.
  • the particles comprising the compound typically have a particle size distribution with a Dv50 of from 0.5 pm to 5.0 pm.
  • the particles preferably have a Dv50 of from 1 .0 pm to 2.0 pm.
  • Particle sizes are described herein by reference to the Dv50 value, which is the median particle size for a volume distribution. Thus, half the volume of the particles have diameters of less than the Dv50 value and half the volume of the particles have diameters of greater than the Dv50 value. This is a well-known manner in which to describe particle size distributions.
  • the technique used to measure the Dv50 values as stated herein is typically laser diffraction.
  • the particle size distribution of the particles comprising the compound may be as measured by laser diffraction using a wet powder dispersion system.
  • the particle size distribution can be measured by laser diffraction using a Malvern Spraytec in conjunction with a wet dispersion cell.
  • the instrument parameters for the Malvern Spraytec are as follows:
  • the particles comprising the compound typically comprise ensifentrine (i.e. ensifentrine free base).
  • the particles may comprise at least 90 wt% ensifentrine free base relative to the total weight of the particles.
  • the particles may comprise at least 99 wt% ensifentrine.
  • the particles may consist of ensifentrine.
  • the concentration of particles comprising the compound in the inhalable pharmaceutical composition is typically from 0.1 to 5.0 mg/mL, preferably from 0.1 to 2.5 mg/mL, more preferably from 1 .0 to 2.0 mg/mL.
  • the inhalable pharmaceutical composition typically further comprises one or more tonicity adjusters, one or more buffers and one or more surfactants.
  • the tonicity adjuster is typically sodium chloride.
  • buffers include a citrate buffer, a phosphate buffer, an acetate buffer, and a bicarbonate buffer.
  • the buffer is a phosphate buffer, for instance sodium dihydrogen phosphate dihydrate and/or disodium phosphate dihydrate.
  • surfactants include lecithin, oleic acid, polyoxyethylene glycol alkyl ethers (for instance PEG 300, PEG 600, PEG 1000, Brij 30, Brij 35, Brij 56, Brij 76 and Brij 97), polypropylene glycol (for instance PPG 2000), glucoside alkyl ethers, polyoxyethylene glycol octylphenol ethers, polyoxyethylene glycol alkylphenol ethers, glycerol alkyl esters, polyoxyethylene glycol sorbitan alkyl esters (polysorbates, for instance polysorbate 20, polysorbate 40, polysorbate 60 and polysorbate 80), sorbitan alkyl esters (for instance sorbitan monolaurate (Span 20), sorbitan monooleate (Span 80) and sorbitan trioleate (Span 85)), cocamide MEA, cocamide DEA, dodecyldimethylamine oxide, block copolymers of polyethylene glycol and polypropylene
  • the one or more surfactants comprise a polysorbate and/or a sorbitan alkyl ester.
  • the one or more surfactants may for instance comprise polysorbate 20 (polyoxyethylene (20) sorbitan monolaurate), polysorbate 40 (polyoxyethylene (20) sorbitan monopalmitate), polysorbate 60 (polyoxyethylene (20) sorbitan monostearate) or polysorbate 80 (polyoxyethylene (20) sorbitan monooleate).
  • the one or more surfactants may for instance comprise sorbitan monolaurate (Span 20), sorbitan monooleate (Span 80) or sorbitan trioleate (Span 85).
  • the sterile liquid vehicle comprises polysorbate 20 and/or sorbitan monolaurate (Span 20).
  • the method may comprise administering to the patient an inhalable liquid pharmaceutical composition comprising:
  • particles consisting of ensifentrine free base at a concentration of from 0.1 to 20 mg/mL;
  • the inhalable liquid pharmaceutical composition may comprise:
  • particles consisting of ensifentrine free base at a concentration of from 0.5 to 6 mg/mL;
  • the compound may be used in combination with a second active agent.
  • the compound may be administered separately or simultaneously with the second active agent.
  • the patient may already be taking a second active agent as a background therapy for COPD.
  • treatment with the second active agent may start at around the same time as treatment with the compound.
  • the compound and the second active agent may be administered in a fixed combination.
  • the second active agent is typically selected from an antibiotic, a macrolide, a muscarinic receptor antagonist, a beta-adrenergic receptor agonist and an inhaled corticosteroid.
  • the compound may accordingly be used in combination with muscarinic receptor antagonist or a beta-adrenergic receptor agonist.
  • the second active agent may be a long-acting muscarinic receptor antagonist (LAMA) or a long- acting beta-adrenergic receptor agonist (LABA).
  • LAMAs include aclidinium, darotropium, tiotropium, glycopyrrolate and umeclidinium.
  • LABAs include salmeterol, formoterol, indacaterol, vilanterol, olodaterol, abediterol and carmoterol.
  • inhaled corticosteroids include beclomethosone, budesonide, fluticasone propionate, ciclesonide, mometasone, fluticasone furoate and pharmaceutically acceptable salts thereof.
  • the compound may accordingly be for use in the treatment of the bronchiectasis (e.g. non-CF bronchiectasis) in combination with a second active agent selected from an antibiotic, a macrolide, a muscarinic receptor antagonist, a beta-adrenergic receptor agonist and an inhaled corticosteroid.
  • a second active agent selected from an antibiotic, a macrolide, a muscarinic receptor antagonist, a beta-adrenergic receptor agonist and an inhaled corticosteroid.
  • the compound is for use in combination with an antibiotic suitable for the treatment of bronchiectasis or a macrolide suitable for the treatment of bronchiectasis.
  • the second active agent is an antibiotic selected from tobramycin, ciprofloxacin, aztreonam and colistin; or the second active agent is a macrolide selected from azithromycin and erythromycin.
  • the invention accordingly provides a second active agent as defined herein for use in the treatment of non-CF bronchiectasis in combination with a compound which is ensifentrine or a pharmaceutically acceptable salt thereof.
  • the compound may alternatively be used as a monotherapy.
  • the compound may be for use in treating bronchiectasis (e.g. non-CF bronchiectasis) as the sole active agent.
  • the compound is not administered in combination with a muscarinic receptor antagonist or a beta-adrenergic receptor agonist.
  • the invention further provides a method of preventing or treating bronchiectasis in a patient, which method comprises administering a therapeutically effective amount of a compound is ensifentrine or a pharmaceutically acceptable salt thereof to the patient, wherein the bronchiectasis is non-cystic fibrosis (non-CF) bronchiectasis.
  • the invention further provides a method of treating bronchiectasis in a patient, which method comprises administering a therapeutically effective amount of a compound is ensifentrine or a pharmaceutically acceptable salt thereof to the patient, wherein the method comprises treating the bronchiectasis by (a) reducing the frequency of cough in the patient and/or (b) reducing sputum production and/or facilitating clearance of mucus from the lungs in the patient.
  • the invention further provides a method of decreasing the frequency and/or severity of bronchiectasis exacerbations in a patient suffering from bronchiectasis, which compound is ensifentrine or a pharmaceutically acceptable salt thereof.
  • the invention further provides use of a compound in the manufacture of a medicament for use in a method of preventing or treating bronchiectasis in a patient, which method comprises administering a therapeutically effective amount of a compound is ensifentrine or a pharmaceutically acceptable salt thereof to the patient, wherein the bronchiectasis is non-cystic fibrosis (non-CF) bronchiectasis.
  • a compound in the manufacture of a medicament for use in a method of preventing or treating bronchiectasis in a patient, which method comprises administering a therapeutically effective amount of a compound is ensifentrine or a pharmaceutically acceptable salt thereof to the patient, wherein the bronchiectasis is non-cystic fibrosis (non-CF) bronchiectasis.
  • non-CF non-cystic fibrosis
  • the invention further provides use of a compound in the manufacture of a medicament for use in a method of treating bronchiectasis in a patient, which method comprises administering a therapeutically effective amount of a compound is ensifentrine or a pharmaceutically acceptable salt thereof to the patient, wherein the method comprises treating the bronchiectasis by (a) reducing the frequency of cough in the patient and/or (b) reducing sputum production and/or facilitating clearance of mucus from the lungs in the patient.
  • Example 1 assessment of ensifentrine in COPD patients with high cough/sputum burden
  • the study population included patients aged 40-80 years with moderate to severe COPD (FEVi 30% - 70% p.n., FEVi/forced vital capacity (FVC) ratio ⁇ 0.7, with mMRC > 2).
  • the randomization stratified (a) the use of stable background maintenance LAMA or LABA therapy use (approx. 50%. yes or no) and (b) cigarette smoking (current or former). Inhaled corticosteroid (ICS) maintenance therapy was permitted in up to 20% of patients under certain provisions.
  • the investigational product and placebo were provided in 2.5 mL unit dose format in an ampule and administered via a nebuliser.
  • the formulation of the investigational product (ensifentrine suspension formulation) and placebo are shown in Table 1 below.
  • E-RS cough and sputum domain results from the phase 3 clinical studies in subjects with cough and sputum scores greater than or equal to mean at baseline (pooled analysis) are shown in Table 2.
  • ensifentrine was found to cause significant improvements in those scores over 6 weeks to 24 weeks, demonstrating activity against sputum production and cough in these patients.
  • the BAL differential cell count provided a total inflammatory cell count so that changes in inflammation following treatment could be observed.
  • the rats were subjected to an intratracheal challenge of either 0.9 % w/v saline or bleomycin, the latter used to induce pulmonary fibrosis.
  • Control 1 subjected 12 rats from the saline challenge group to daily administration of the vehicle suspension article via inhalation for the full 21 days.
  • Control 2 subjected 12 rats from the bleomycin challenge group to daily administration of the vehicle suspension article via inhalation for the full 21 days.
  • Table 3 The experimental set-up is summarised in Table 3 below.
  • the rats were sacrificed and the BAL differential cell counts and the TGF- concentration data were collected.
  • TGF-P concentration at day 21 was also lower in the rats following ensifentrine treatment compared to those of the bleomycin Control 2.
  • inhaled ensifentrine can reduce macrophage infiltration in the airways in a rat model of pulmonary fibrosis.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne un composé destiné à être utilisé dans une méthode de prévention ou de traitement de la bronchectasie chez un patient, lequel composé est l'ensifentrine ou un sel pharmaceutiquement acceptable correspondant, la bronchectasie étant la bronchiectasie à fibrose non kystique. L'invention concerne également un composé destiné à être utilisé dans une méthode de traitement de la bronchectasie chez un patient, lequel composé est l'ensifentrine ou un sel pharmaceutiquement acceptable correspondant, la méthode comprenant le traitement de la bronchectasie par (a) la réduction de la fréquence de la toux chez le patient et/ou (b) la réduction de la production d'expectorations et/ou la facilitation de la clairance du mucus des poumons chez le patient.
PCT/GB2024/051144 2023-11-01 2024-04-30 Ensifentrine pour le traitement de la bronchectasie Pending WO2025093848A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363595018P 2023-11-01 2023-11-01
US63/595,018 2023-11-01

Publications (1)

Publication Number Publication Date
WO2025093848A1 true WO2025093848A1 (fr) 2025-05-08

Family

ID=91082269

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2024/051144 Pending WO2025093848A1 (fr) 2023-11-01 2024-04-30 Ensifentrine pour le traitement de la bronchectasie

Country Status (1)

Country Link
WO (1) WO2025093848A1 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000058308A1 (fr) 1999-03-31 2000-10-05 Vernalis Limited Derives de pyrimido [6,1-a] isoquinolein-4-one et leur utilisation en medecine
WO2014140647A1 (fr) * 2013-03-15 2014-09-18 Verona Pharma Plc Association de médicaments
WO2015173551A1 (fr) 2014-05-12 2015-11-19 Verona Pharma Plc Nouveau traitement
WO2024033626A1 (fr) * 2022-08-08 2024-02-15 Verona Pharma Plc Ensifentrine (rpl-554) pour diminution de fréquence et/ou de gravité d'exacerbations de bpco

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000058308A1 (fr) 1999-03-31 2000-10-05 Vernalis Limited Derives de pyrimido [6,1-a] isoquinolein-4-one et leur utilisation en medecine
WO2014140647A1 (fr) * 2013-03-15 2014-09-18 Verona Pharma Plc Association de médicaments
WO2014140648A1 (fr) * 2013-03-15 2014-09-18 Verona Pharma Plc Association médicamenteuse
WO2015173551A1 (fr) 2014-05-12 2015-11-19 Verona Pharma Plc Nouveau traitement
WO2024033626A1 (fr) * 2022-08-08 2024-02-15 Verona Pharma Plc Ensifentrine (rpl-554) pour diminution de fréquence et/ou de gravité d'exacerbations de bpco

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
"E-RS (EXACT-Respiratory Symptoms),", USER MANUAL (VERSION 3.0), October 2014 (2014-10-01)
MARIO CAZZOLA ET AL: "Ensifentrine (RPL554): an inhaled 'bifunctional' dual PDE3/4 inhibitor for the treatment of asthma and chronic obstructive pulmonary disease", PHARMACEUTICAL PATENT ANALYST, vol. 7, no. 6, 1 November 2018 (2018-11-01), GB, pages 249 - 257, XP055651020, ISSN: 2046-8954, DOI: 10.4155/ppa-2018-0030 *
MARTIN CLÉMENCE ET AL: "Inhaled Dual Phosphodiesterase 3/4 Inhibitors for the Treatment of Patients with COPD: A Short Review", THE INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, vol. Volume 16, 1 August 2021 (2021-08-01), pages 2363 - 2373, XP093186750, ISSN: 1178-2005, Retrieved from the Internet <URL:https://www.dovepress.com/getfile.php?fileID=72702> [retrieved on 20240717], DOI: 10.2147/COPD.S226688 *
SCIURBA F.C. ET AL: "Ensifentrine, a Novel Dual Phosphodiesterase (PDE) 3 and 4 Inhibitor, Significantly Improves COPD Symptoms and Quality of Life in the Phase 3 Enhance-1 Trial", C40. CLINICAL TRIALS AND NOVEL INTERVENTIONS IN COPD, 1 May 2023 (2023-05-01), pages A5007 - A5007, XP093186756, Retrieved from the Internet <URL:https://www.atsjournals.org/doi/epdf/10.1164/ajrccm-conference.2023.207.1_MeetingAbstracts.A5007?role=tab> [retrieved on 20240717], DOI: 10.1164/ajrccm-conference.2023.207.1_MeetingAbstracts.A5007 *
WATZ HENRIK ET AL: "Symptom Improvement Following Treatment with the Inhaled Dual Phosphodiesterase 3 and 4 Inhibitor Ensifentrine in Patients with Moderate to Severe COPD - A Detailed Analysis", THE INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, vol. Volume 15, 1 January 2020 (2020-01-01), pages 2199 - 2206, XP093186771, ISSN: 1178-2005, Retrieved from the Internet <URL:https://www.dovepress.com/getfile.php?fileID=61502> [retrieved on 20240717], DOI: 10.2147/COPD.S263025 *

Similar Documents

Publication Publication Date Title
US20240165055A1 (en) Treatment
CN111249260A (zh) 包含rpl554的液体吸入制剂
JP2020023537A (ja) Ｃｏｐｄの治療のためのチオトロピウムブロミド、フォルモテロール及びブデソニドの組み合わせ
JP2008110991A (ja) 処置方法
WO2016178019A1 (fr) Solution de nébulisation de tiotropium stable
US20240165023A1 (en) Liquid pharmaceutical composition
US20240382489A1 (en) Liquid pharmaceutical composition
WO2024084212A1 (fr) Traitement de la fibrose pulmonaire idiopathique avec de l&#39;ensifentrine
RU2611665C2 (ru) Улучшенный состав суспензии кортикостероида для ингаляционного введения
WO2025093848A1 (fr) Ensifentrine pour le traitement de la bronchectasie
EP4188327B1 (fr) Thérapie combinée pour administration par inhalation
WO2025168546A1 (fr) Ensifentrine pour le traitement de la bpco
TWI905086B (zh) 包含雷芬那新（ｒｅｖｅｆｅｎａｃｉｎ）之醫藥組合物用於治療慢性阻塞性肺疾病之用途及選擇治療用之吸入遞送裝置之方法
RU2614716C2 (ru) Фармацевтическая композиция для применения назальным введением, содержащая кортикостероид и хинолон или фузидовую кислоту

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24725929

Country of ref document: EP

Kind code of ref document: A1